Differing effect of systemic anti psoriasis therapies on platelet physiology - a case report and review of literature

BMC Dermatology

Volumn 10, Issue , 2010, Pages

  Davidovici, Batya B ^a   Sullivan Whalen, Mary M ^a   Gilleaudeau, Patricia ^a   Krueger, James G ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIPSORIASIS AGENT; CYCLOSPORIN A; EFALIZUMAB; ETANERCEPT; IBUPROFEN; INTERLEUKIN 6; IRON; TUMOR NECROSIS FACTOR ANTIBODY; IMMUNOSUPPRESSIVE AGENT;

ADULT; ANEMIA; ARTHRALGIA; ARTICLE; CARDIOVASCULAR DISEASE; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DRUG WITHDRAWAL; ERYTHEMA; FAMILY HISTORY; HIGH RISK PATIENT; HUMAN; MALE; PHOTOTHERAPY; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; RADIODIAGNOSIS; THROMBOCYTOSIS; THROMBOSIS; TREATMENT RESPONSE; ULTRAVIOLET B RADIATION; BLOOD; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; PSORIASIS; REVIEW; THROMBOCYTE; THROMBOCYTE COUNT;

ADULT; BLOOD PLATELETS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; PLATELET COUNT; PSORIASIS; THROMBOCYTOSIS;

EID: 77950373727     PISSN: None     EISSN: 14715945     Source Type: Journal    
DOI: 10.1186/1471-5945-10-2     Document Type: Article

References (38)

1. Langley RG, Krueger GG, Griffiths CE. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis 2005, 64(Suppl 2):ii18-23. discussion ii24-15., 10.1136/ard.2004.033217, 1766861, 15708928.
2. Schon MP, Boehncke WH. Psoriasis. N Engl J Med 2005, 352(18):1899-1912. 10.1056/NEJMra041320, 15872205.
3. Koo J. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin 1996, 14(3):485-496. 10.1016/S0733-8635(05)70376-4, 8818558.
4. Christophers E. Psoriasis--epidemiology and clinical spectrum. Clin Exp Dermatol 2001, 26(4):314-320. 10.1046/j.1365-2230.2001.00832.x, 11422182.
5. Rapp SR, Feldman SR, Exum ML, Fleischer AB, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999, 41(3 Pt 1):401-407. 10.1016/S0190-9622(99)70112-X, 10459113.
6. Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol 1995, 32(6):982-986. 10.1016/0190-9622(95)91336-X, 7751469.
7. Gelfand JM, Troxel AB, Lewis JD, Kurd SK, Shin DB, Wang X, Margolis DJ, Strom BL. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol 2007, 143(12):1493-1499. 10.1001/archderm.143.12.1493, 18086997.
8. McDonald CJ, Calabresi P. Psoriasis and occlusive vascular disease. Br J Dermatol 1978, 99(5):469-475. 10.1111/j.1365-2133.1978.tb02012.x, 708620.
9. Mallbris L, Akre O, Granath F, Yin L, Lindelof B, Ekbom A, Stahle-Backdahl M. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol 2004, 19(3):225-230. 10.1023/B:EJEP.0000020447.59150.f9, 15117115.
10. Naldi L, Chatenoud L, Linder D, Belloni Fortina A, Peserico A, Virgili AR, Bruni PL, Ingordo V, Lo Scocco G, Solaroli C, Schena D, Barba A, Di Landro A, Pezzarossa E, Arcangeli F, Gianni C, Betti R, Carli P, Farris A, Barabino GF, La Vecchia C. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol 2005, 125(1):61-67. 10.1111/j.0022-202X.2005.23681.x, 15982303.
11. Collins CE, Rampton DS. Review article: platelets in inflammatory bowel disease--pathogenetic role and therapeutic implications. Aliment Pharmacol Ther 1997, 11(2):237-247. 10.1046/j.1365-2036.1997.153328000.x, 9146760.
12. Harries AD, Beeching NJ, Rogerson SJ, Nye FJ. The platelet count as a simple measure to distinguish inflammatory bowel disease from infective diarrhoea. J Infect 1991, 22(3):247-250. 10.1016/S0163-4453(05)80006-4, 2071905.
13. Yasumoto S, Imayama S, Hori Y. Increased serum level of interleukin-6 in patients with psoriatic arthritis and thrombocytosis. J Dermatol 1995, 22(10):718-722.
14. Ertenli I, Kiraz S, Ozturk MA, Haznedaroglu I, Celik I, Calguneri M. Pathologic thrombopoiesis of rheumatoid arthritis. Rheumatol Int 2003, 23(2):49-60.
15. Firmin D, Roguedas AM, Lemasson G, Abgrall JF, Misery L. Eczematous dermatosis and thrombocytosis induced by efalizumab: two new side effects. Dermatology 2008, 217(3):203-206. 10.1159/000141958, 18594143.
16. Philippeaux MM, Vesin C, Tacchini-Cottier F, Piguet PF. Activated human platelets express beta2 integrin. Eur J Haematol 1996, 56(3):130-137.
17. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, Leeb B, Breedveld FC, Macfarlane JD, Bijl H, Woody JN. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994, 344(8930):1105-1110. 10.1016/S0140-6736(94)90628-9, 7934491.
18. Haznedaroglu IC, Ertenli I, Ozcebe OI, Kiraz S, Ozdemir O, Sayinalp NM, Dundar SV, Calguneri M, Kirazli S. Megakaryocyte-related interleukins in reactive thrombocytosis versus autonomous thrombocythemia. Acta Haematol 1996, 95(2):107-111. 10.1159/000203857, 8638438.
19. Ertenli I, Haznedaroglu IC, Kiraz S, Celik I, Calguneri M, Kirazhi S. Cytokines affecting megakaryocytopoiesis in rheumatoid arthritis with thrombocytosis. Rheumatol Int 1996, 16(1):5-8. 10.1007/BF01419947, 8783415.
20. Heits F, Stahl M, Ludwig D, Stange EF, Jelkmann W. Elevated serum thrombopoietin and interleukin-6 concentrations in thrombocytosis associated with inflammatory bowel disease. J Interferon Cytokine Res 1999, 19(7):757-760. 10.1089/107999099313604, 10454346.
21. Ceresa IF, Noris P, Ambaglio C, Pecci A, Balduini CL. Thrombopoietin is not uniquely responsible for thrombocytosis in inflammatory disorders. Platelets 2007, 18(8):579-582. 10.1080/09537100701593601, 18041648.
22. Alenius GM, Eriksson C, Rantapaa Dahlqvist S. Interleukin-6 and soluble interleukin-2 receptor alpha-markers of inflammation in patients with psoriatic arthritis?. Clin Exp Rheumatol 2009, 27(1):120-123.
23. Goodman WA, Levine AD, Massari JV, Sugiyama H, McCormick TS, Cooper KD. IL-6 signaling in psoriasis prevents immune suppression by regulatory T cells. J Immunol 2009, 183(5):3170-3176. 10.4049/jimmunol.0803721, 19648274.
24. Storogenko M, Pech-Amsellem MA, Kerdine S, Rousselet F, Pallardy M. Cyclosporin-A inhibits human endothelial cells proliferation through interleukin-6-dependent mechanisms. Life Sci 1997, 60(17):1487-1496. 10.1016/S0024-3205(97)00100-8, 9126869.
25. LaSpina M, Tripathi S, Gatto LA, Bruch D, Maier KG, Kittur DS. An interleukin-6-neutralizing antibody prevents cyclosporine-induced nephrotoxicity in mice. J Surg Res 2008, 148(2):121-125. 10.1016/j.jss.2007.12.786, 2536771, 18561950.
26. Williamson MS, Miller EK, Plemons J, Rees T, Iacopino AM. Cyclosporine A upregulates interleukin-6 gene expression in human gingiva: possible mechanism for gingival overgrowth. J Periodontol 1994, 65(10):895-903.
27. Haider AS, Lowes MA, Suarez-Farinas M, Zaba LC, Cardinale I, Khatcherian A, Novitskaya I, Wittkowski KM, Krueger JG. Identification of cellular pathways of "type 1," Th17 T cells, and TNF- and inducible nitric oxide synthase-producing dendritic cells in autoimmune inflammation through pharmacogenomic study of cyclosporine A in psoriasis. J Immunol 2008, 180(3):1913-1920.
28. Brennan FM, Chantry D, Jackson A, Maini R, Feldmann M. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 1989, 2(8657):244-247. 10.1016/S0140-6736(89)90430-3, 2569055.
29. Haworth C, Brennan FM, Chantry D, Turner M, Maini RN, Feldmann M. Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-alpha. Eur J Immunol 1991, 21(10):2575-2579. 10.1002/eji.1830211039, 1915559.
30. Charles P, Elliott MJ, Davis D, Potter A, Kalden JR, Antoni C, Breedveld FC, Smolen JS, Eberl G, deWoody K, Feldmann M, Maini RN. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol 1999, 163(3):1521-1528.
31. Collins CE, Cahill MR, Newland AC, Rampton DS. Platelets circulate in an activated state in inflammatory bowel disease. Gastroenterology 1994, 106(4):840-845.
32. Kasperska-Zajac A, Brzoza Z, Rogala B. Platelet function in cutaneous diseases. Platelets 2008, 19(5):317-321. 10.1080/09537100802082249, 18791936.
33. Hayashi S, Shimizu I, Miyauchi H, Watanabe S. Increased platelet aggregation in psoriasis. Acta Derm Venereol 1985, 65(3):258-262.
34. Berrettini M, Parise P, Constantini V, Grasselli S, Nenci GG. Platelet activation in psoriasis. Thromb Haemost 1985, 53(2):195-197.
35. Tamagawa-Mineoka R, Katoh N, Ueda E, Masuda K, Kishimoto S. Elevated platelet activation in patients with atopic dermatitis and psoriasis: increased plasma levels of beta-thromboglobulin and platelet factor 4. Allergol Int 2008, 57(4):391-396. 10.2332/allergolint.O-08-537, 18797178.
36. Ludwig RJ, Schultz JE, Boehncke WH, Podda M, Tandi C, Krombach F, Baatz H, Kaufmann R, von Andrian UH, Zollner TM. Activated, not resting, platelets increase leukocyte rolling in murine skin utilizing a distinct set of adhesion molecules. J Invest Dermatol 2004, 122(3):830-836. 10.1111/j.0022-202X.2004.22318.x, 15086572.
37. Kragballe K, Fallon JD. Increased aggregation and arachidonic acid transformation by psoriatic platelets: evidence that platelet-derived 12-hydroxy-eicosatetraenoic acid increases keratinocyte DNA synthesis in vitro. Arch Dermatol Res 1986, 278(6):449-453. 10.1007/BF00455162, 2431657.
38. Schafer AI. Thrombocytosis and thrombocythemia. Blood Rev 2001, 15(4):159-166. 10.1054/blre.2001.0162, 11792116.